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Abstract
CD22 functions primarily as a negative regulator of B-cell receptor signaling. The Cd22a allele has
been proposed as a candidate allele for murine systemic lupus erythematosus. In this study, we
explored the possible expression of aberrant forms of CD22, which differ in the N-terminal sequences
constituting the ligand-binding site due to synthesis of abnormally processed Cd22 mRNA, in several
Cd22a mouse strains, including C57BL/6 Cd22 congenic mice. The staining pattern of splenic B cells
obtained with CY34 anti-CD22 mAb, which was expected to bind poorly to the aberrant CD22, was
more heterogeneous in Cd22a mice than in Cd22b mice. Moreover, CD22 detected on B cells of Cd22a
mice was expressed more weakly and as a smaller-sized protein, compared with Cd22b mice.
Significantly, analysis with a synthetic CD22 ligand demonstrated that Cd22a mice carried a larger
proportion of CD22 that was not bound by cis ligands on the B-cell surface than Cd22b mice. Finally,
the study of C57BL/6 Cd22 congenic mice revealed that Cd22a B cells displayed a phenotype
reminiscent of constitutively activated B cells (reduced surface IgM expression and augmented MHC
class II expression), as reported for B cells expressing a mutant CD22 lacking the ligand-binding
domain. Our demonstration that Cd22a B cells express aberrant forms of CD22, which can potentially
deregulate B-cell signaling because of their decreased ligand-binding capacity, provides further
support for Cd22a as a potential candidate allele for murine systemic lupus erythematosus.
Introduction
CD22 is a B cell-specific member of the Ig superfamily with
seven Ig-like domains, which functions as an adhesion recep-
tor recognizing a2,6-linked sialic acid (2,6Sia)-bearing gly-
cans on target cells, and as a co-receptor for B-cell receptor
(BCR) (1). Upon BCR cross-linking, CD22 is rapidly tyrosine
phosphorylated on its cytoplasmic tail, which results in recruit-
ment and activation of SH-2 phosphotyrosine phosphatase
(SHP-1), thereby negatively regulating BCR signaling (2).
Furthermore, the finding that CD22-deficient B cells exhibit
a greatly enhanced and prolonged Ca2+ signal after BCR
stimulation (3–6) indicates that CD22 functions primarily as
a negative regulator of BCR signaling by controlling the
threshold of BCR-mediated signal transduction. CD22-
deficient B cells also show higher tyrosine phosphorylation
of several signaling molecules which positively regulate Ca2+
mobilization (1). One mechanism by which CD22 regulates
Ca2+ signaling has recently been uncovered: CD22 attenuates
calcium efflux by activating a plasma membrane calcium-
ATPase, the activation of which requires tyrosine phosphory-
lation of CD22 and SHP-1 (7).
CD22 is a member of the sialic acid-binding Ig-like lectin
(Siglec) family of adhesion receptors, which bind specifically
to sialic acids in characteristic linkages (8). CD22 has a
specificity for 2,6Sia, a common structure on N-linked glycans
that are abundantly expressed on the surface of many cells
(9, 10). CD22 binds to 2,6Sia with its first Ig-like domain
(11, 12). The affinity of CD22 for sialic acids is very low and
does not differ greatly for several sialylated proteins, suggest-
ing that it is just the presence and density of the carbohydrate,
but not the protein backbone, that determines ligand binding
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(13). It has been shown that CD22 is constitutively bound
to ligands in cis, i.e. to ligands on the same cellular surface,
on the majority of both human and mouse B cells (14–16).
These cis interactions seem to regulate the inhibitory sig-
naling function of CD22, because when they were blocked in
established B-cell lines, lower tyrosine phosphorylation of
CD22 and higher Ca2+ signaling after BCR activation were
observed (17, 18). Recently, a CD22 knock-in mouse with
a mutated CD22 ligand-binding domain confirmed the
important biological role of 2,6Sia binding for CD22 (19).
However, enhanced Ca2+ signaling was not observed in this
knockin mouse.
The CD22a protein carries a 6-amino-acid deletion and
8-amino-acid substitutions in the first Ig-like domain, as com-
pared with CD22b (20). In addition, we have demonstrated that
the Cd22a gene contains a short interspersed nucleotide
element insertion in the second intron (21). As a consequence,
Cd22a B cells synthesize abnormally processed Cd22 mRNA,
which contains insertions of ~20–120 nucleotides between
exons 2 and 3, and/or deletions of ~100–190 nucleotides in
exon 4 encoding the first Ig-like domain of CD22. Thus, it has
been speculated that Cd22a B cells could express aberrant
forms of CD22, which differ in the N-terminal sequences
constituting the ligand-binding site (17, 18, 22). We explored
this possibility by assessing the binding to B cells of two
different anti-CD22 mAb, CY34 and NIM-R6, which apparently
recognize an epitope present in the first or fourth Ig-like
domain, respectively (22, 23), and by analyzing the expres-
sion of aberrant CD22 protein from Cd22a mice by Western
blot. In addition, we determined the binding capacity of B cells
from different mouse strains bearing either theCd22a orCd22b
allele for a synthetic ligand containing 2,6Sia. Our results
demonstrate that a larger proportion of CD22 is not bound by
cis ligand on Cd22a B cells, as compared with Cd22b B cells,
indicating the expression of aberrant forms of CD22 with
a decreased ligand-binding capacity in Cd22a mice.
Methods
Mice
C57BL/6 (B6; Cd22b), BALB/c (Cd22b), C3H (Cd22b), DBA/2
(Cd22a), NZB (Cd22a) and NZW (Cd22a) mice were pur-
chased from the Jackson Laboratories, Bar Harbor, ME, USA.
CD22/ mice with a pure B6 background were developed as
described previously (6). B6 mice bearing the Cd22a allele
were generated by backcross procedures using marker-
assisted selection, as described previously (24).
Flow cytometric analysis
Flow cytometry was performed using two-color staining of
lymphocytes, and analyzed with a FACSCalibur (BD Bio-
sciences, San Jose, CA, USA). The following antibodies and
reagents were used: FITC-labeled NIM-R6 rat anti-CD22 (20),
FITC-labeled CY34 rat anti-CD22 (25), FITC-labeled rat IgG,
polyclonal rabbit anti-CD22 antibodies, raised against Ig-like
domains 1–3 of the CD22b protein by immunizing rabbits with
a CD22 domains 1–3-Fc fusion protein, and affinity purified
(the expression construct was generously provided by A. van
der Merwe, Oxford and P. Crocker, Dundee), FITC-labeled
goat anti-rabbit IgG, FITC- or PE-labeled RA3-6B2 rat anti-
B220, PE-labeled 53-7.3 rat anti-CD5, biotinylated 7G6 rat
anti-CD21, FITC-labeled LO-MM9 rat anti-mouse IgM and
FITC-labeled Y-3P anti-I-Ab.
Western blot analysis
Total lysates of spleen cells from 2-month-old B6, BALB/c,
DBA/2 and NZB mice were separated by a 6% SDS-PAGE
and transferred to Immobilon-P transfer membrane (Millipore,
Volketswil, Switzerland) with a semi-dry blotting apparatus
(BioRad, Glattbrugg, Switzerland). After 2 h of blocking at
room temperature in TTBS (10 mM Tris–HCl, pH 7.4, 100 mM
NaCl and 0.05% Tween 20) containing 5% low-fat, dry milk
powder (TTBS-MP), the membranes were incubated with
polyclonal rabbit anti-CD22 antibodies in TTBS-MP overnight
at 4C. Polyclonal rabbit anti-LYN antibodies (Santa Cruz
Biotechnology, Heidelberg, Germany) were used as a load-
ing control. Thoroughly washed membranes were incubated
with HRP-conjugated goat anti-rabbit IgG (BioRad) for 1 h at
room temperature. Chemiluminescence development was
carried out with the enhanced chemiluminescence reagents
(Amersham Bioscience, Du¨bendorf, Switzerland) and the
membranes were exposed to HyperFilm ECL (Amersham).
Cell culture
A total of 2 3 106 spleen cells from a pool of 2-month-old
mice were incubated in 1 ml of DMEM containing 10% FCS
in Falcon 24-well plates in the presence of 25 lg ml1 LPS for
48 h. Then, the expression of CD22 on B cells was determined
by flow cytometric analysis. B cells were purified from spleen
by adherence of macrophages to plastic plates for 1 h at
37C and subsequent treatment with anti-Thy-1.2 (AT-83) mAb
in the presence of rabbit complement. The purity of B cells, as
documented by cytofluorometric analysis, was superior to
95%. B-cell proliferative responses were determined by
incubating 2 3 105 spleen cells from B6 mice with different
concentrations of rat b7-6 anti-mouse IgM mAb, rat FGK45
anti-mouse CD40mAb or LPS in a total volume of 200 ll DMEM
containing 10% FCS. Cultures were pulsed with 1 lCi of
[3H]thymidine for the final 6 h of 3-day culture, harvested
and counted for radioactivity.
Staining of cells with a synthetic CD22 ligand
Preparation and use of the synthetic probe, N-glycolylneuramic
acid–galactose–N-acetylglucosamine–streptavidin–alkaline
phosphatase (NeuGca2,6Gal–SAAP), have been described
in detail elsewhere (16). NeuGca2,6Gal–SAAP consists of
the sialoside NeuGca2,6Gala1,4GlcNAc–biotin, bound to
streptavidin–alkaline phosphatase, which is then FITC-labeled.
The probe used for the experiments here is a new preparation
which gives a higher degree of background staining with
CD22/ B cells, than previously (16). For staining, single-
cell suspensions were prepared from total spleen. Prior to
FACS analysis, all cells were depleted of erythrocytes by lysis
with hypotonic Gey’s solution. Sialidase treatment was
performed with 0.1 U ml1 neuraminidase of Arthrobacter
ureafaciens (Roche Applied Science, Mannheim, Germany)
for 1 h at 37C in PBS-0.1% BSA. A total of 1 3 105 to 2 3 105
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erythrocyte-depleted splenic cells were first stained with anti-
B220 mAb. Staining with FITC-labeled NeuGca2,6Gal–SAAP
was performed by incubating the cells with the probe for 45
min on ice. Flow cytometry was performed as described
above.
Ca2+ mobilization measurements
Spleen cells were loaded with Indo-1 (Molecular Probes,
Eugene, OR, USA), as described (17, 18), and stained with
FITC-labeled anti-B220 mAb. Splenocytes were then stimu-
lated with 10, 30 or 90 lg ml1 of b7-6 anti-IgM mAb at 37C,
and increases in intracellular free Ca2+ in B220+ B cells were
measured in real time with the use of a FACSVantage (BD
Biosciences). The recorded files were transferred to FlowJo
software (Tree Star, Ashland, OR, USA), and the median of
each sample was calculated.
Results
Heterogeneous staining pattern of Cd22a B cells with
CY34, but homogeneous staining pattern with NIM-R6
When splenic B cells from 2-month-old DBA/2 (Cd22a), NZB
(Cd22a), NZW (Cd22a), B6 (Cd22b) and BALB/c (Cd22b) mice
were stained with FITC-labeled CY34 mAb, the intensity of
surface staining on Cd22a B220+ B cells, gated using PE-
labeled anti-B220 mAb, was lower than that of Cd22b B cells
(Fig. 1). Moreover, it was striking to see that the staining
pattern of B cells with the CY34 mAb was more heterogeneous
in the three strains of mice bearing the Cd22a allele than
that ofCd22b B6 and BALB/c mice (Fig. 1). In contrast, splenic
B cells from the three different Cd22a strains exhibited
a homogeneous staining pattern by FITC-labeled NIM-R6
mAb, similar to that observed in Cd22b mice. Notably, the
intensity of NIM-R6 staining on Cd22b B cells was significantly
higher than that observed on Cd22a B cells, although the
differences were relatively small (P < 0.005). These results
suggested that, unlike CD22 expressed by mice carrying the
Cd22b allele, CD22 molecules on B cells from mice bearing
the Cd22a allele were more heterogeneous because of
differences in their N-terminal region. This is consistent with
the finding that Cd22a B cells express multiple forms of
Cd22 mRNA transcripts having highly variable N-terminal
sequences coding for the first Ig-like domain.
Expression of smaller-sized CD22 proteins in Cd22a B cells
than in Cd22b B cells
To further address whether aberrant forms of CD22 protein
are expressed in B cells of Cd22a mice, splenic B cells
were analyzed with a polyclonal rabbit anti-CD22 antibody
raised against murine CD22b (Ig-like domains 1–3). Western
blot analysis revealed that CD22migrated as a slightly smaller-
sized protein in B cells fromCd22amice (DBA/2 and NZB) than
CD22 detected in B cells from Cd22b mice (B6 and BALB/c)
(Fig. 2A). We also noted lower intensities of the CD22 bands in
Cd22a mice. This was confirmed by flow cytometric analysis,
showing that the intensity of rabbit anti-CD22 staining on the
surface of Cd22a B cells was significantly lower than that on
the surface of Cd22b B cells (Fig. 2B). These differences could
be explained by two reasons: a lower expression of CD22
protein by Cd22a mice and a lower reactivity to CD22a of the
rabbit anti-CD22 antibodies used in this analysis because
these antibodies were raised against a polypeptide spanning
the first three Ig-like domains in which substantial amino-acid
substitutions were identified between the CD22a and CD22b
proteins (22, 23).
Fig. 1. Heterogeneous staining pattern of Cd22a B cells with CY34
mAb, but homogeneous staining pattern with NIM-R6 mAb. Spleen
cells from 2-month-old DBA/2 (Cd22a), NZB (Cd22a), NZW (Cd22a),
B6 (Cd22b) and BALB/c (Cd22b) mice were stained with either FITC-
labeled CY34 or NIM-R6 anti-CD22 mAb. Histograms show represen-
tative results of CY34 and NIM-R6 staining on B220+ B cells obtained
from five to seven individual mice. Mean fluorescence intensities
(6SD) of CY34 and NIM-R6 staining of each strain of mice are indi-
cated. Differences between Cd22a and Cd22b mice for both stainings
were significant (P < 0.005 by the Wilcoxon two-sample test). Shaded
histograms indicate the background staining of B cells with FITC-
labeled control rat IgG conjugates, except for B6 mice, where shaded
histograms indicate the staining of B cells from CD22/ B6 mice with
FITC-labeled CY34 or NIM-R6 anti-CD22 mAb.
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Limited up-regulation of CD22 bearing the CY34 epitope in
Cd22a B cells stimulated with LPS
We have previously observed, by staining with NIM-R6 mAb,
that B cells of NZW (Cd22a) mice up-regulated CD22 less
efficiently after activation with LPS in the presence of IL-4 than
those of B6 (Cd22b) mice (21). To further define the expression
of aberrant and intact CD22 in Cd22a B cells, we compared
the level of CD22 molecules detectable by CY34 or NIM-R6
mAb after incubation of spleen cells with LPS. After 48 h of
LPS stimulation, splenic B cells from Cd22a (DBA/2, NZB and
NZW) mice displayed increases in CD22 levels detectable
by NIM-R6 mAb, though less than those observed in Cd22b
(B6 and BALB/c) mice (Fig. 3). In contrast, the level of CD22
recognized by CY34 mAb was barely increased in Cd22a
B cells, as compared with Cd22b B cells, probably due to the
presence of CD22 molecules with an aberrant first Ig-like
domain that were poorly detected by CY34 mAb. Significantly,
after LPS stimulation of splenic B cells from NZW and NZB
mice, we observed a substantial increase in the number of
B cells expressing aberrant CD22, which was very poorly
recognized by the CY34 mAb. It should be mentioned that
the CY34lo subset did not express CD5 at a significant level
(data not shown), indicating that these were not B-1 cells
present in high numbers in NZBmice (26). Since an expansion
of the CY34lo subset was not observed in LPS-stimulated spleen
cells from non-autoimmune DBA/2 mice, this finding is likely
related to the particular genetic background of autoimmune-
prone NZW and NZB mice. All these data support the ex-
pression of aberrant forms of CD22 on the surface of Cd22a
B cells.
Increased binding by Cd22a B cells to a synthetic
CD22 ligand
Since the CD22a protein carries mutations in exon 4 coding
for the ligand-binding first Ig-like domain (20), we tested
whether sialic acid binding is affected by these mutations. To
examine the ligand-binding capacity of CD22a in situ on the
surface of B cells, we used a synthetic probe, NeuGca2,6Gal–
SAAP which carries 2,6Sia coupled as an oligomer to strepta-
vidin. As previously described (16), most CD22 on the surface
of B cells of B6 mice (Cd22b) was ‘masked’ by binding to
endogenous ligands in cis and therefore could not be stained
by the probe NeuGca2,6Gal–SAAP (Fig. 4A). However, there
was a sub-population (~10%) of B cells with ‘unmasked’ CD22,
which could be stained with NeuGca2,6Gal–SAAP. Next, we
compared the NeuGca2,6Gal–SAAP binding with B cells from
three strains of Cd22b mice with three strains of Cd22a mice.
The Cd22b strains B6, BALB/c and C3H showed on average
10–11% of B cells which were stained with the probe (Fig. 4A).
In contrast, for the Cd22a strains NZB, NZW and DBA/2 probe
binding to B cells was significantly increased (1.5- to 1.8-fold).
This indicated a higher degree of unmasked, i.e. not cis-
bound, CD22 in the Cd22a strains. Not all probe binding was
CD22 specific, as can be seen by staining of B cells from
CD22-deficient mice. Residual binding of NeuGca2,6Gal–
SAAP to CD22/ B cells could be due to other Siglecs ex-
pressed, or could be unspecific binding.
Then, we tested the capacity of CD22a and CD22b to bind
the synthetic probe after removal of cis ligands from the
surface of B cells by sialidase treatment. After a treatment
with sialidase, B cells from all CD22-sufficient mice showed in-
creased binding of the NeuGca2,6Gal–SAAP probe (Fig. 4B).
However, under the sialidase treatment conditions used,
there was still a difference between B cells from Cd22b and
Cd22a mice, and B cells from Cd22a mice showed a clearer
shift toward probe-stained cells. As expected, the majority of
Fig. 2. Expression of smaller-sized CD22 proteins in Cd22a B cells
than Cd22b B cells. (A) Western blot analysis of CD22 protein
expression in Cd22a (DBA/2 and NZB) and Cd22b (B6 and BALB/c)
B cells. Total lysates of spleen cells from 2-month-old mice were
analyzed by SDS-PAGE with subsequent immunoblot analysis with
rabbit anti-CD22 or anti-LYN antibodies. 1: B6, 2: DBA/2, 3: NZB,
4: BALB/c. One representative result from two independent experi-
ments is shown. (B) Spleen cells from the indicated mice were stained
with rabbit anti-CD22 antibodies, followed by FITC-labeled goat anti-
rabbit IgG. Histograms show representative results of anti-CD22
staining on B220+ B cells, with mean fluorescence intensities from
three individual mice. Shaded histograms indicate background
staining of B cells with FITC-labeled goat anti-rabbit IgG conjugates
alone.
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CD22/ B cells still failed to bind the probe after this treat-
ment (Fig. 4B). These results indicate that not all 2,6Sia-
containing CD22 ligands on CD22b-expressing cells can be
removed by sialidase treatment as easily as on CD22a-
expressing cells, suggesting that the former are less acces-
sible. It should, however, be mentioned thatCd22a B cells from
NZB, NZW and DBA/2 mice did not show any significant
differences in Ca2+ influx following BCR cross-linking with
b7-6 anti-IgM mAb at any dose tested, as compared with
Cd22b B cells from B6, BALB/c and C3H mice (data not
shown).
Defective expression of CD22 in B cells from B6 Cd22a
congenic mice
In order to exclude that the observed differences between
Cd22a and Cd22b mice are due to unspecific strain back-
ground effects, B6 Cd22a congenic mice were produced by
backcross procedures and analyzed for the staining of splenic
B cells with different anti-CD22 antibodies in comparison
with that of Cd22b B cells from conventional B6 mice. As
observed in different strains of Cd22a and Cd22b mice, B6
Cd22a B cells displayed weak and heterogeneous staining
with CY34 mAb, and less strong staining with NIM-R6 mAb
and polyclonal rabbit anti-CD22 antibodies, as compared
with conventional B6 Cd22b B cells (Fig. 5A). Moreover,
Western blot analysis confirmed the expression of a smaller-
sized CD22 protein in B6 Cd22a B cells than in Cd22b B cells
(Fig. 5B). Furthermore, the binding study with synthetic
NeuGca2,6Gal–SAAP probe on untreated and sialidase-
treated B cells demonstrated the presence of a larger
proportion of unmasked CD22 on B6 Cd22a B cells than on
B6 Cd22b B cells (P < 0.05; Fig. 6). Notably, the analysis of
B-cell subsets in spleen by staining with anti-IgM and anti-
CD21 mAb revealed that percentages of transitional 1 (T1;
CD21IgMhi), T2 and marginal zone (CD21hiIgMhi), and
follicular (CD21intIgMint) B cells in B6 Cd22a mice (means 6
SD of three mice: T1, 6.6 6 0.4%; T2 + marginal zone, 5.3 6
0.7%; follicular, 45.1 6 1.9%) were essentially identical to
those from B6 Cd22b mice (T1: 7.2 6 1.1%; T2 + marginal
zone: 6.4 6 0.9%; follicular: 43.2 6 0.2%). These data argued
against the possibility that an imbalance in splenic B-cell
subsets accounted for the higher unmasking of CD22 in
Cd22a mice.
Activated phenotype of B cells from B6 Cd22a
congenic mice
Studies with B cells expressing a mutant CD22 lacking the
ligand-binding domain displayed a phenotype of constitutively
activated B cells, as documented by reduced expression of
IgM and increased expression of MHC class II on the surface
of mature B cells (19). Therefore, we determined expression
levels of surface IgM and MHC class II I-A molecules on
splenic B cells from B6 Cd22a mice in comparison with those
on Cd22b B cells. Cd22a B cells were found to express
significantly less surface IgM (mean fluorescence intensity:
59.9 6 2.0) and more MHC class II I-A (172.0 6 5.7) than
B cells from Cd22b counterparts (IgM, 65.66 0.6; I-A, 151.16
8.1; Fig. 7A).
It has also been reported that anti-IgM- and anti-CD40-
induced B-cell proliferative responses were substantially
reduced and modestly augmented, respectively, in mice
expressing the mutant CD22 (19). Although we did not
observe measurable differences in B-cell proliferative re-
sponses after stimulation with anti-CD40 mAb or LPS, BCR-
induced proliferation after treatment with anti-IgM mAb was
substantially reduced in Cd22a B cells, compared with that
of Cd22b B cells (Fig. 7B). Despite significant reduced
proliferative responses, Cd22a B cells had Ca2+ mobilization
comparable to that of Cd22b B cells after stimulation with
anti-IgM mAb (Fig. 7C), consistent with the results obtained
with B cells expressing the mutant CD22 (19).
Fig. 3. Altered activation-induced up-regulation of surface CD22 on
splenic B cells from Cd22a and Cd22b mice. Spleen cells from 2-
month-oldCd22a (DBA/2, NZB and NZW) andCd22b (B6 and BALB/c)
mice were incubated with 25 lg ml1 of LPS for 48 h, and the
expression levels of CD22 were assessed using FITC-labeled CY34
and NIM-R6 anti-CD22 mAb. Fluorescence intensities on stimulated
(dark lines) and unstimulated (shaded) B220+ B cells are shown.
Representative results of three independent experiments are shown.
Note a lack of up-regulation of CD22 detectable by CY34mAb on LPS-
stimulated B cells from Cd22a (DBA/2, NZB and NZW) mice, and
a significant expansion of the CY34lo B-cell population in LPS-
stimulated B cells from NZW and NZB mice. Although we noted
some variations in LPS-induced B-cell proliferative responses, as
determined by specific uptake of [3H]thymidine, among various
strains of mice (mean counts per minute 6 1 SD of three mice: DBA/
2, 77 6186 9934; NZB, 82 7986 6338; NZW, 62 0546 10 418; B6, 83
2186 10 472; BALB/c, 50 0276 4058), no consistent differences were
observed between Cd22a and Cd22b strains of mice.
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Discussion
We explored the possible expression of aberrant forms of
CD22 on B cells from several Cd22a mouse strains, including
Cd22a congenic C57BL/6 mice, by surface staining with
CY34 and NIM-R6 anti-CD22 mAb, which recognize distinct
epitopes of CD22, by Western blot, and by use of a synthetic
CD22 ligand. Our data support the notion that Cd22a B cells
express aberrant forms of CD22 molecule that differ in the
N-terminal region constituting the ligand-binding site for
2,6Sia-bearing glycans, as compared with CD22b molecules.
The analysis with a synthetic CD22 ligand revealed that
CD22 protein from Cd22a mice is less bound to endogenous
ligands on the B-cell surface than their counterpart from
Cd22b strains, indicating a decreased ligand-binding cap-
acity of CD22a protein. This was further supported by the
analysis of B6 Cd22 congenic mice, which revealed that
Cd22a B cells displayed a phenotype reminiscent of consti-
tutively activated B cells, as characterized by reduced surface
IgM expression and augmented MHC class II expression,
similar to that reported for B cells expressing a mutant
CD22 lacking the ligand-binding domain (19).
The full-length CD22a protein carries a 6-amino-acid de-
letion plus several point mutations in the first Ig-like domain, in
comparison to the CD22b protein (20). These mutations map to
the C9 and C$ b-strands of one b-sheet, as can be deduced
Fig. 4. Higher proportion of B cells bearing unmasked CD22 in Cd22a mice than in Cd22b mice. (A) Untreated splenocytes of Cd22a (NZB, NZW
and DBA/2) and Cd22b (B6, BALB/c and C3H) mice were stained with PE-labeled anti-B220 and FITC-labeled NeuGca2,6Gal–SAAP. This probe
detects CD22 molecules, which are not bound by endogenous ligands, i.e. unmasked CD22. Mean percentages (61 SD) of B220+ B cells that
bind NeuGca2,6Gal–SAAP (upper right quadrant) are indicated. Significance by Student’s t-test (n¼ 3): NZB versus B6: P< 0.05; NZW versus B6:
P< 0.01; DBA/2 versus B6: P< 0.01. Similar statistically significant differences were obtained when Cd22amice were compared with BALB/c and
C3H mice. (B) Splenocytes were pre-treated with sialidase to remove sialic acids from the cellular surface and then stained. The proportion of
probe-bound B cells after sialidase treatment was higher in Cd22a than in Cd22b mice, as shown by mean percentages (61 SD) in upper right
quadrants. Significance by Student’s t-test (n ¼ 3): NZB versus B6, BALB/c, C3H: not significant; NZW versus B6, BALB/c, C3H: P < 0.01; DBA/2
versus B6, BALB/c, C3H: P < 0.01. This was also corroborated by the mean fluorescence intensities of all B220+ cells: B6 CD22/: 5, B6: 13,
BALB/c: 10, C3H: 11, NZB: 18, NZW: 22, DBA/2: 17. One representative result of three independent experiments is shown.
Fig. 5. Defective expression of CD22 in B cells from B6 Cd22a
congenic mice. (A) Spleen cells from 2-month-old Cd22a and Cd22b
B6 mice were stained with CY34, NIM-R6 or rabbit anti-CD22
antibodies. Histograms show representative results of anti-CD22
staining on B220+ B cells obtained from three individual mice
(a, Cd22a; b, Cd22b). Shaded histograms indicate the background
staining of B cells with FITC-labeled control conjugates alone.
(B) Western blot analysis of CD22 protein expression in B6 Cd22a
and Cd22b B cells. Total lysates of splenic cells from 2-month-old
micewere analyzed by SDS-PAGEwith subsequent immunoblot analy-
sis with rabbit anti-CD22 or anti-LYN antibodies (a, Cd22a; b, Cd22b).
Fig. 6. Higher proportion of B cells bearing unmasked CD22 in B6
Cd22a mice than in B6 Cd22b mice. (A) Untreated splenocytes of
2-month-old Cd22a and Cd22b B6 mice were stained with PE-labeled
anti-B220 and FITC-labeled NeuGca2,6Gal–SAAP. Mean percentages
(61 SD of three mice) of B220+ B cells that bind NeuGca2,6Gal–SAAP
(upper right quadrant) are indicated. (B) Splenocytes were pre-treated
with sialidase to remove sialic acids from the cellular surface and then
stained. The proportion of probe-bound cells after sialidase treatment
was higher in Cd22a than in Cd22b mice, as shown by mean per-
centages (61 SD) in upper right quadrants.
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from the protein structure of sialoadhesin (27) and align-
ment of CD22 sequence with the sialoadhesin (28). These C9
and C$ b-strands are far away from the sialic acid-binding
pocket of the Siglecs, which is formed by b-strands A, F and
G (27). Therefore, the mutations present in these ‘normal’
forms of the CD22a protein are unlikely to affect the sialic acid-
binding site and to change the affinity of CD22 ligands.
In addition to the mutation mentioned above, Cd22a also
carries a short interspersed nucleotide element insertion in
the second intron, leading to abnormal splicing of Cd22a
mRNA (21). Thus, aberrant CD22 molecules are likely ex-
pressed on Cd22a B cells with substantial deletions in the
first Ig-like domain which constitutes the ligand-binding site
(21). Western blot analysis shows a slightly lower running
CD22 protein in B cells from Cd22a mice. This supports the
possible expression of truncated isoforms of CD22, since
the observed difference cannot be explained by a 6-amino-
acid deletion present in the full-length CD22a protein, as com-
pared with the CD22b protein (849 amino acids). Based on
the sequence analysis on nine different aberrant CD22 mRNA
species in Cd22a mice (21), we expect that at least two
isoforms (mCD22-VII and VIII) could express truncated
forms of CD22, which have additional deletions of 34 and
62 amino acids. Notably, three others are likely to be un-
expressed because of the presence of a premature stop
codon. Since the relative abundance of these different
CD22 mRNA transcripts has not been estimated, it is difficult
to define the expression levels of aberrant CD22 proteins in
relation to those of full-length CD22 protein. Clearly, further
biochemical analysis is awaited to determine whether the
majority of CD22 expressed in Cd22a mice are indeed the
truncated isoforms of CD22.
Possible expression of aberrant forms of CD22 likely im-
pairs the binding of anti-CD22 CY34mAb. The epitope for CY34
binding has been mapped to arginine at position 120 in the
first Ig-like domain, in close vicinity to arginine at position 130,
which is highly conserved within the Siglec family and required
for sialic acid binding (28). Therefore, the ligand-binding
capacity of the aberrant forms of CD22a is likely to be affected.
In addition, it should also be stressed that one of the truncated
isoforms (mCD22-VII) possibly expressed in Cd22a B cells
lacks arginines at position 130 and 137 (21), which are
involved in the ligand-binding activity (19). Thus, a decreased
ability of the aberrant CD22a proteins to bind to endogenous
cis ligands could explain the higher degree of unmasked
CD22 on the surface of B cells from Cd22a mice that we
observed in experiments using synthetic 2,6Sia-containing
probe. Significantly, we also observed that sialidase-treated
Cd22a B cells displayed a more pronounced increase in
binding of this probe, as compared with Cd22b B cells. This
could be due to the fact that more of the CD22b protein is
bound in cis, thus rendering the sialic acids on Cd22b B cells
less accessible to sialidase treatment than on their Cd22a
counterparts. However, it should be stressed that CD22a
efficiently binds this artificial ligand, probably because of
a higher avidity of the synthetic ligand than of the endogenous
cis ligands, due to its oligomeric structure.
Additionally, expression of CD22a might affect homodime-
rization of CD22. Indeed, an N-linked potential glycosylation
site is missing in the first Ig-like domain of CD22a, due to the
6-amino-acid deletion present in the Cd22a gene (23). In the
CD22b molecule, this glycosylation site may carry carbo-
hydrates, including 2,6Sia, which can be sterically well ac-
cessible to the sialic acid-binding domain, also present in the
first Ig-like domain. Indirect evidence for such a model of
homodimerization comes from experiments in which sialylation
of CD22 protein prevented CD22-mediated adhesion (29).
Defective homodimerization could provide an alternative
explanation why a higher fraction of CD22 is unbound in cis
Fig. 7. B-cell phenotypes and B-cell proliferative and Ca2+ flux re-
sponses in B6 Cd22a and Cd22b congenic mice. (A) Spleen cells from
2-month-old B6 Cd22a and Cd22b mice were stained with a combina-
tion of anti-B220, anti-IgM and anti-I-Ab mAb. Results are expressed
as mean fluoresence intensity obtained with anti-IgM and anti-I-A
staining of B220+ B cells. Each symbol represents an individual
Cd22a and Cd22b mice, and mean values are indicated by horizontal
lines. Significance by Student’s t-test: IgM: P < 0.01; I-A: P < 0.05.
(B) Splenic B-cell proliferative responses following stimulation with
25 lg ml1 of b7-6 anti-IgM mAb, FGK45 anti-CD40 mAb or LPS in B6
Cd22a and Cd22b mice. Results are expressed as counts per minute
of [3H]thymidine ([3H]Tdr) incorporation (means of three mice61 SD).
Background uptake of [3H]Tdr was 1109 6 70 for Cd22a B cells and
979 6 47 for Cd22b B cells. Significance by Student’s t-test: anti-IgM,
P < 0.05; anti-CD40 and LPS, not significant. (C) Spleen cells were
loaded with Indo-1, stained with FITC-labeled anti-B220 mAb and
then stimulated with 30 lg ml1 of b7-6 anti-IgM mAb at 37C.
Increases in intracellular free Ca2+ in B220+ B cells were measured in
real time with the use of a FACSVantage. The arrow shows addition of
anti-IgM mAb. Representative results of three independent experi-
ments are shown.
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onCd22a B cells, but more experiments are needed to test this
possibility.
Impaired ligand binding by CD22 in cis on the B-cell surface
has previously been shown to affect BCR signaling. When
CD22 ligand binding was prevented by a genetic or pharma-
cological approach, anti-IgM-stimulated B cells showed less
tyrosine phosphorylation of CD22, less SHP-1 recruitment
and a higherCa2+mobilization (17, 18). However, a recently es-
tablished CD22 knock-in mouse with a mutation in the ligand-
binding domain of CD22 did not confirm these findings (19). In
fact, we were unable to demonstrate significant differences
in Ca2+ influx after anti-IgM stimulation of B cells between
the various Cd22a and Cd22b mouse strains. Nevertheless, it
should be stressed that B cells expressing a mutant CD22
lacking the ligand-binding domain displayed a phenotype
of activated B cells, which is characterized by reduced IgM
expression and augmented MHC class II expression, similar
to that of CD22/ B cells (3–6), and that CD22 ligand bind-
ing was involved in the regulation of BCR-mediated B-cell
proliferation (19). Our analysis of B6 Cd22 congenic mice
revealed that Cd22a B cells exhibit an activated phenotype
(i.e. reduced surface IgM expression and increased surface
MHC class II expression) similar to those of B cells expressing
the mutant CD22. In view of the importance of CD22–CD22
ligand interaction in the regulation of B-cell activation, our
data support the idea that the expression of the defective
Cd22a could contribute to enhanced B-cell activation, and
thus favor the development of autoimmune responses in
combination with other susceptibility alleles present in lupus-
prone mice.
The expression of aberrant CD22 molecules in Cd22a mice
may have significant consequences for B-cell responses to
antigen, and in particular for the spontaneous production of
autoantibodies. A recent study suggested that simultaneous
interactions between B cells and target cells via BCR–auto-
antigen and CD22–CD22 ligand could be a mechanism to
prevent activation of potentially autoreactive B cells (30). Thus,
in Cd22a mice, lower basal expression levels and defective
up-regulation of CD22 on potentially autoreactive B cells
could favor the production of autoantibodies by reducing
the BCR signaling threshold. In agreement, deficiency in
CD22 expression, even at a heterozygous level, was able to
promote the production of IgG anti-DNA autoantibodies in
B6 mice (3, 21, 31). Interval mapping analysis for lupus sus-
ceptibility loci revealed that an NZW locus that peaked in the
vicinity of the Cd22a gene was strongly linked with auto-
antibody production and lupus-like glomerulonephritis (32–
34). More recently, we have shown that B6 mice bearing an
NZB chromosome 7 interval encompassing the Cd22a gene
spontaneously develop lupus-like autoimmune syndrome (24).
Clearly, further assessment of the functional capacities of the
different allelic forms of CD22 and of the regulation of CD22
expression will help to better understand the role of CD22
polymorphism in the development of B-cell-mediated autoim-
mune diseases.
Acknowledgements
We thank Mr Guy Brighouse and Mr Giuseppe Celetta for their
excellent technical help. We thank the Consortium for Functional
Glycomics for providing reagents. This work was supported by grants










SHP-1 SH-2 phosphotyrosine phosphatase
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